Michelson awarded grant to develop mini optical probe
This article was originally published in Clinica
The UK government’s Technology Strategy Board has awarded Michelson Diagnostics a £25,000 grant. The money will be used to fund a study into the feasibility of miniaturised optical coherence tomography (OCT) probes for cancer diagnosis. The probes are intended to be attached to the Orpington, UK-based firm’s VivoSight multi-beam OCT scanner, which it CE marked for sale in Europe in October. The scanner is designed to provide images of sub-surface tissue at a "far higher" resolution than other imaging modalities, allowing visualisation of the epidermis, dermis and sub-surface blood vessels. Michelson is hoping to advance the product further via development partnerships with firms such as suppliers of miniature components and commercial partners.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.